Immutep will announce the new TACTI-002 and INSIGHT-004 data in



SYDNEY, Australia, April 28, 2021 (GLOBE NEWSWIRE) – Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), the leading developer of LAG-3-related immunotherapy treatments for cancer and autoimmune disease, is pleased to announce that new data from its studies TACTI-002 and INSIGHT-004 are expected to be featured in three poster presentations at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO), which is taking place online as a meeting this year from June 4-8.

Abstracts will be available starting at 5:00 p.m. EST on May 19, 2021. Poster presentations containing new and updated data that are not part of the abstract will be posted on ASCO.org at the times indicated below and will then be available on the Immutep website at www.immutep.com.

In addition, Immutep plans to host a post-ASCO webcast to discuss the data and results, as well as to provide an update on the Company’s activities.

TACTI-002 posters
Title: Results of a phase II study of soluble eftilagimod alpha (LAG-3 protein) and pembrolizumab in patients with unselected PD-L1 metastatic non-small cell lung carcinoma.
Session title: Poster Session: Lung Cancer – Non-Small Cell Metastatic
Dated: On-demand session available from 9 a.m. on June 4, 2021 EST
Presenter: Dr Tim Clay, Researcher, St John of God Subiaco Hospital, Perth, Australia
Abstract: 9046
Title: Results of a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with unselected second-line metastatic squamous cell carcinoma of the head and neck PD-L1.
Session title: Poster Session: Head and Neck Cancer
Dated: On-demand session available from 9 a.m. on June 4, 2021 EST
Presenter: Dr Irene Brana, researcher, Vall d’Hebron Institute of Oncology, Barcelona, ​​Spain
Abstract: 6028
INSIGHT-004 Poster
Title: Phase I INSIGHT Platform Trial: Advanced Safety and Efficacy Data from Stratum D Evaluating the Feasibility and Safety of Soluble Eftilagimod alpha (LAG-3 Protein) Associated with Avelumab in advanced solid tumors.
Session title: Discussion poster session, Developmental Therapeutics – Immunotherapy
Dated: On-demand session available from 9 a.m. on June 4, 2021 EST
Presenter: Thorsten Oliver Goetze, MD; Krankenhaus Nordwest, University Cancer Center Frankfurt and Institut für Klinische Krebsforschung IKF GmbH am Krankenhaus Nordwest, Frankfurt am Main, Germany
Abstract: 2518

About the American Society of Clinical Oncology (ASCO) Conference
ASCO’s annual meeting represents the world’s largest gathering of medical oncologists, industry representatives, researchers, patient advocates and investment analysts to discuss clinical research and cutting-edge therapies in oncology, and for information on improving cancer care. For more information on the ASCO 2021 Annual Meeting, please visit https://www.asco.org/

About TACTI-002
TACTI-002 (Two ACTive Immunotherapies) is a Phase II clinical trial conducted in collaboration with Merck & Co., Inc., Kenilworth, NJ, USA (known as “MSD” outside of the United States and from Canada). The study evaluates the combination of efti with MSD’s KEYTRUDA® (pembrolizumab) in up to 183 patients with squamous cell carcinoma of the head and neck or non-small cell lung cancer at first and second intention.

About INSIGHT-004 (also called INSIGHT Stratum D)
INSIGHT-004 is a Phase I clinical trial and is the fourth installment of the investigator-initiated INSIGHT trial which is being conducted by the IKF Clinical Cancer Research Institute at Krankenhaus Nordwest in Frankfurt. It is being conducted as part of Immutep’s collaboration with Merck KGaA and Pfizer Inc., and is evaluating the safety, tolerability and recommended dose of phase II efti when co-administered with avelumab , a human anti-PD-L1 antibody, in 12 cancer patients. Avelumab is co-developed and co-marketed by Merck KGaA, Darmstadt, Germany and Pfizer Inc.

About Immutep
Immutep is a globally active biotechnology company that is a leader in the development of immunotherapeutics related to LAG-3 for the treatment of cancer, infectious diseases and autoimmune diseases. Immutep is dedicated to leveraging its technology and expertise to bring innovative treatment options to market for patients and maximize shareholder value. Immutep is listed on the Australian Securities Exchange (IMM) and NASDAQ (IMMP) in the United States.

Immutep’s current lead product candidate is eftilagimod alpha (“efti” or “IMP321”), a soluble LAG-3 protein, which is a first-class antigen-presenting cell (APC) activator currently being explored in the world. cancer and infectious diseases. Immutep is also developing an LAG-3 agonist (IMP761) for autoimmune diseases. Other LAG-3 products, in particular antibodies for modulating the immune response, are under development by Immutep’s major pharmaceutical partners.

Further information can be found on the company’s website www.immutep.com or by contacting:

Australian Investors / Media:
Catherine Strong, Citadelle-MAGNUS
+61 (0) 406 759 268; [email protected]

American media:
Tim McCarthy, LifeSci Advisors
+1 (212) 915.2564; [email protected]



Source link

Previous Immunoma SARS-CoV-2 antibody cocktail neutralizes UK, South Africa, Brazil and California variants in preclinical testing; Progress to IND repository
Next SK Innovation obtains 3.6 tril. Won for investment in batteries, environmentally friendly materials

No Comment

Leave a reply

Your email address will not be published. Required fields are marked *